to treat osteoporosis. 5, 6) In particular, vitamin D plays a key role in calcium metabolism in bone tissue. Moreover, it is also one elemental nutrient that contributes to homeostasis and the stabilization of neural tissue. 
Introduction
Osteoporosis is characterized by a low bone mass and structural change of bony tissue. 4) Therefore, patients with osteoporosis are at increased risk of developing osteoporotic fracture.
The World Health Organization (WHO) defines osteoporosis as a spinal or hip BMD of 2.5 standard deviations or more below the mean for healthy, young women (T-score of -2.5 or below)
as measured by dual energy x-ray absorptiometry. 16) Moreover, with the increasing number of elderly people in our population, the prevalence of osteoporosis and osteoporotic fracture has also increased along with interest in the treatment of patients with osteoporosis. 1, 2, 3) In patients diagnosed with osteoporosis, the optimal treatment regimens include fall prevention, an appropriate intake of calcium and vitamin D and the use of various drugs containing bisphosphonate. 4) There has been an increased tendency towards the use of various therapeutic agents, such as bisphosphonate, parathyroid hormone, calcium and vitamin D www.krspine.org 16 risk of developing hip fracture and non-vertebral fracture can be reduced with the administration of vitamin D at a daily dosage of 700-800 IU. 13) To date, there have also been reports that the risk of vertebral fractures was decreased with the use of various drugs, including bisphosphonate. 14) However, few studies about the correlation between the use of vitamin D and the decreased incidence of vertebral fractures in patients with osteoporosis exist. 15) Therefore, the purpose of this study was to investigate serum levels of vitamin D in elderly patients with OSCF diagnosed with osteoporosis. Serum levels of vitamin D were also compared between the two groups with consideration for age, sex and seasonal variations. In all patients, we also evaluated the correlation between serum levels of vitamin D and factors such as age, BMD and bone turnover markers.
Materials and Methods

Selection criteria
From October 2008 to December 2012, we evaluated the vitamin D and bone turnover markers of 1,033 patients aged 60 years or older who visited the outpatient clinic of our medical institution. We performed a retrospective analysis of these patients' medical records. All the patients were divided into two groups: the fracture group and the control group.
Exclusion criteria for the current study were as follows ( (1) Vertebral fracture due to high-energy trauma that is defined according to the fracture morphology and patient's history.
(2) Past history of taking drugs that may affect bone metabolism.
(3) Osteoporosis who were currently taking anti-osteoporotic drugs or vitamins or had a past history of taking such drugs.
(4) Underlying diseases associated with bone metabolism, such as a bone tumor or hematooncologic, renal, hepatic, rheumatoid, or endocrine diseases.
(5) Past history of fractures related to osteoporosis (distal radius, proximal femur, and spine).
(6) Past history of spine surgery.
(7) T-score of BMD higher than -2.5.
A diagnosis of spinal fracture was based on plain x-ray and computed tomography. Magnetic resonance imaging was used for further evaluation that assists to figure the appearance of spinal fracture. Thus, 95 patients were assigned to the OSCF group and 118 patients to the control group (Fig. 1 ).
In 15) In the fracture group, the blood sampling was performed 
Comparative analysis
We also compared the mean serum levels of 25(OH)D 3, BMD and bone turnover markers between the two groups. In addition, after the patients were divided into subgroups according to age, season and sex, we compared the vitamin D levels between the two groups.
Correlation analysis
In all participants, we analyzed the correlations between serum levels of 25(OH)D 3 and factor such as age, BMD and bone turnover markers.
Statistical analysis
We used Student's t-test to compare the age, sex, serum levels of 25(OH)D 3 bone turnover markers in each season and BMD.
To identify the correlations between vitamin D, age, BMD, and bone turnover markers, we performed a Pearson correlation analysis. A p-value < 0.05was used to define significance.
Statistical analysis was performed using SAS for Windows version 9.2 (SAS Institute Inc., Cary, NC).
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Results
The mean age of the patients was 72.63±6.63 years (range, was significantly lower in the fracture group than in the control group (Table 2) . T-score was significantly lower in the fracture group .For the bone turnover markers, only serum C-telopeptide levels were significantly higher in the fracture group (Table 3) .
According to age and sex, serum 25(OH)D 3 levels were not significantly different in the two study groups. When seasonal variation was considered, vitamin D levels were significantly lower in the fracture group in autumn compared to the control group, but the differences were not statistically significant in spring, summer and winter.
Regardless of the presence of fracture, summer and autumn had higher levels of serum 25(OH)D 3 than spring and winter (Table 4) .
Correlation analysis
We analyzed whether serum 25(OH)D 3 levels had a significant correlation with age, BMD, osteocalcin, and C-telopeptide in all patients. These levels had a weak negative correlation with age as well as a weak positive correlation with BMD. However, serum 25(OH)D 3 levels had no significant correlation with osteocalcin and C-telopeptide (Table 5 ). But, we found that the OSCF has correlation with serum 25(OH)D 3 levels using Pearson's correlation coefficient and regression analysis. (Table 6 , 7)
Discussion
Our results showed that serum 25(OH)D 3 levels were significantly lower in the fracture group as compared with the non-fracture group. In previous studies, vitamin D deficiency is reportedly prevalent in patients with osteoporotic fracture.
Moreover, it has also been reported that appropriate vitamin D supplement therapy lowers the prevalence of fracture.
13)
Moniz et al. 17) found that 94% of patients with osteoporotic hip to contribute to preventing the occurrence of bone fracture. 5, 12, 21) Presumably, patients with a vitamin D deficiency might be at increased risk of worsening osteoporosis and sustaining a fall injury. This risk increases the incidence of OSCF. It can therefore be inferred that serum 25(OH)D 3 levels were lower in the fracture group. But, in the current study, we analyzed the correlation between BMD and serum 25(OH)D 3 levels. We found that there was a weak positive correlation between them.
Further large cohort study has to be performed for reveal the correlation between BMD and serum 25(OH)D 3 levels.
In the present study, we also compared serum 25(OH)D 3 levels between the seasons in both groups and found that they were significantly higher in summer and autumn as compared with winter and spring. 24) The assay of such bone turnover markers is a non-invasive test regimen, but is disadvantageous, however, due to a high degree of intrapersonal variation. The accuracy also can be decreased depending on such factors as circadian variation, daily variation, dietary intake or exercise. 25) Garnero et al. 26) conducted the EPIDOS study to identify the correlation between hip joint fracture and bone turnover markers using a prospective design in elderly patients; they found that osteocalcin had no significant correlation with the risk of developing hip fracture and C-telopeptide had a significant correlation with developing bone fracture irrespective of the severity of osteoporosis. Baseline osteoblastic markers before the fracture showed no significant difference in the patients with hip fracture as compared with their age-matched controls, and osteoclastic bone markers were significantly higher. Bjarnason et al. 27 ) also reported that there was no significant correlation between osteocalcin and vertebral osteoporotic fracture. Bauer et al. 28) also found that C-telopeptide correlated significantly with the occurrence of incidental vertebral fracture. Our results were also consistent with these reports. Osteocalcin had no significant correlation with fracture. But, C-telopeptide was higher in fracture group more than control group.
It has also been reported that bone turnover markers are additionally associated with various factors; such as age, sex, and intrinsic hormone, bone metabolism following the onset of bone fracture, intraday and interday variation, dietary intake and exercise, as well as vitamin D. 8, 29, 30) In the current study, we analyzed the correlation between vitamin D and bone turnover markers (osteocalcin and C-telopeptide) and found no significant correlation.
Our results were showed the difference in that we could 22, 23) We failed to consider the correlation between these factors. It is a way to solve this weakness of our paper using multivariate analysis in a f
Conclusion
Serum 25(OH)D 3 levels were lower in patients with OSCF than they were in the control group, but, correlation is weak. We suggest the necessity for revealing the correlation. We suppose that maintaining appropriate serum 25(OH)D 3 levels in patients with osteoporosis might be correlation with preventing the occurrence of OSCF. Nevertheless, further studies are warranted to examine whether vitamin D supplementation could lower the incidence of OSCF in elderly people with osteoporosis.
